ADVFN US – Market Content Editor
-

Hot Inflation Data and Nvidia Slide Pull Wall Street Lower as Rate Hike Bets Build
U.S. stocks ended lower on Tuesday after a hotter-than-expected consumer price report strengthened the case for a Federal Reserve rate hike in December. Treasury yields jumped on the news, with the 10-year yield moving close to 5%, and a steep drop in Nvidia added extra pressure to the tech-heavy Nasdaq. The losses were orderly rather…
-

PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
PepGen Inc. (NASDAQ:PEPG) reported third-quarter 2026 financial results alongside new Phase 2 clinical data for PGN-EDODM1, its investigational treatment for myotonic dystrophy type 1 (DM1). The biotechnology company ended September with $104.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028. The company also announced results from the…
-

MIND CTI Agrees to $25.4 Million Acquisition by Enghouse Systems, Reports Q3 2026 Results
MIND C.T.I. Ltd. (NASDAQ:MNDO) announced an agreement to be acquired by Enghouse Systems Ltd. (TSX:ENGH) in an all-cash transaction valued at approximately $25.4 million. The company also reported third-quarter 2026 financial results and appointed Orly Sorokin as its new Chief Executive Officer. Under the merger agreement, Enghouse will acquire all outstanding MIND CTI shares for…
-

Pixelworks Signs Multi-Year Agreement with Meta to Bring TrueCut Motion Technology to VR Devices
Pixelworks, Inc. (NASDAQ:PXLW) announced a multi-year partnership and device certification agreement with Meta to bring its TrueCut Motion cinematic technology to Meta’s virtual reality devices, including the upcoming Meta VR Glasses. The agreement will enable certified Meta devices to support a growing catalogue of films, television series and immersive 3D content mastered using Pixelworks’ TrueCut…
-

City Therapeutics Doses First Participant in Phase 1 Trial of Stargardt Disease Treatment CITY-RBP4
City Therapeutics, Inc. (NASDAQ:CTY) announced that the first participant has been dosed in its Phase 1 clinical trial evaluating CITY-RBP4, an investigational RNA interference (RNAi) treatment for Stargardt disease, an inherited retinal condition associated with progressive vision loss. The biotechnology company expects to report initial clinical data from the study in mid-2027. Phase 1 Trial…
-

Aurora Mobile’s EngageLab Supports Purrrr’s Global IoT Cat Rescue Platform
Aurora Mobile Limited (NASDAQ:JG) announced that Purrrr, an international Internet of Things (IoT) platform focused on stray cat care and rescue, has integrated its EngageLab AppPush technology to support real-time notifications and user engagement across its network of smart feeding devices. Purrrr currently operates more than 20,000 smart feeders across 200 cities in over 10…
-

TriSalus Life Sciences Reports 11.3% Q3 Revenue Growth to $12.9 Million, Revises 2026 Guidance
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) reported third-quarter 2026 revenue of $12.9 million, an increase of 11.3% year-on-year, supported by higher sales volumes of its TriNav drug delivery systems. The oncology medical technology company also revised its full-year revenue guidance to between $46 million and $48 million. The company reported improved gross margins and reduced operating…
-

Rubico Agrees to Acquire Two MR Tankers as Potential Revenue Backlog Rises 40% to $523 Million
Rubico Inc. (NASDAQ:RUBI) announced an agreement to acquire two newbuilding medium-range (MR) tankers through a $14.5 million transaction with related party Top Ships Inc., increasing its potential gross revenue backlog by approximately 40% to $523.1 million, including optional charter extensions. The acquisition involves purchasing two companies holding shipbuilding contracts for 47,499 deadweight tonne (dwt) chemical…

